Repros get IRB approval for low-dose Proellex study


REPROS THERAPEUTICS RECEIVES INVESTIGATIONAL REVIEW BOARD APPROVAL TO COMMENCE LOW DOSE FOR PROELLEX® STUDY AT ICON SITE
Company to provide regular updates on study progress


THE WOODLANDS, Texas - July 22, 2010 - Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.


The Company plans to report the results after each patient dosing group has completed the 10 week dosing period. Based on previous work the Company anticipates that all five doses will be safe. Although the Company believes that both the 1 and 3 mg dose will not yield any efficacy signal due to the low levels of projected absorbed drug, those doses were required by the FDA to assure patient safety at higher doses in light of the liver toxicity exhibited at 50 mg. The Company believes that roughly 80% of women at the 12 mg dose will exhibit changes in menstrual patterns that translate to clinical benefit for both uterine fibroids and endometriosis. The benefits expected are significant reduction in menstrual bleeding and reduction in menstrual pelvic pain. Since the Company does not have human experience at doses lower than 12.5 mg it is difficult to project what efficacy signal might be observed below 12 mg.


In addition to healthy volunteers the protocol allows for the recruitment of women with uterine fibroids, endometriosis, heavy menstrual bleeding or menstrual pelvic pain as these women should see benefit at an effective dose. Previously a dose of 12.5 mg Proellex achieved highly statistically significant results compared to placebo (p<0.0001) when assessing quality of life improvements and excessive menstrual bleeding in women with uterine fibroids. In a small study there was no statistical difference in reduction in pain scores in women with endometriosis when Proellex was compared to Lupron®. Unlike Lupron, Proellex caused no change in markers of bone mineral density, a side effect which limits the duration that a woman can take Lupron.


The Company expects to commence dosing of the 1 mg cohort in August or early September. The cost of the entire study is well within the cash resources Repros currently has on hand. The Company believes it can have reportable data from the 12 mg group within roughly 18 months after starting the 1 mg subject group.


About Repros Therapeutics Inc.


Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.